RecruitingEarly Phase 1NCT06613841

Multitracer [18F]Fluciclovine and 18F-FDG PET, and Advanced MRI for Metabolic Profiling of Glioblastoma

Pilot Study to Evaluate Multitracer [18F]Fluciclovine and 18F-FDG PET, and Advanced MRI Methods at 7Tesla Metabolic Profiling of Glioblastoma


Sponsor

Abramson Cancer Center at Penn Medicine

Enrollment

15 participants

Start Date

May 1, 2025

Study Type

INTERVENTIONAL

Conditions

Summary

* To perform metabolic phenotyping of treatment naïve and recurrent GBM by multitracer \[18F\]Fluciclovine and 18F-FDG PET. * To compare uptake measures of 18F-Fluciclovine and 18F-FDG and MRI quantification of glutamate and lactate levels to tumor tissue laboratory assays (RNA seq and proteomics) of glutamine/glutamate, glucose, and lactate metabolism. * To perform metabolic phenotyping of treatment naïve and recurrent GBM by advanced MRI methods at 7 Tesla


Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This study uses multiple advanced brain imaging scans — including two types of PET tracers and specialized MRI — to build a detailed picture of how glioblastoma (an aggressive brain tumor) uses energy and nutrients. Better metabolic profiling could help doctors understand tumor behavior and plan more targeted treatments. **You may be eligible if...** - You are 18 years old or older - You have a new brain mass suspected or confirmed to be glioblastoma - Or you have a previously treated glioblastoma showing signs of possible recurrence on imaging **You may NOT be eligible if...** - You are unable to have MRI or PET scans (e.g., metal implants, claustrophobia) - You are pregnant or breastfeeding - You have a serious medical condition that makes the imaging procedures unsafe Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGFluciclovine F18

To perform metabolic phenotyping of treatment naïve and recurrent GBM by multitracer \[18F\]Fluciclovine and 18F-FDG PET.


Locations(2)

Hospital of the University of Pennsylvania

Philadelphia, Pennsylvania, United States

University of Pennsylvania

Philadelphia, Pennsylvania, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06613841


Related Trials